COVID-19

Recce Pharmaceuticals (ASX:RCE) has entered into a Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases, with partnership and funding from the Defense Threat Reduction Agency. 

Radiopharm Theranostics (ASX:RAD) has announced the dosing of the first patient in its US Phase 2b imaging study of 18F-RAD101 in suspected recurrent brain metastasis.

Dimerix (ASX:DXB) has provided an update on its ACTION3 Phase 3 clinical trial of DMX-200 in a rare kidney disease, Focal Segmental Glomerular Sclerosis

Research led by Monash University has found that a commonly used diabetes medicine can reduce the pain of people with knee osteoarthritis and overweight or obesity, possibly delaying the need for knee replacements.

At its March meeting, surrounded by controversy following the decision to defer multiple submissions, the Pharmaceutical Benefits Advisory Committee delivered recommendations for high-profile cancer therapies, including one funded outside the PBS before it was approved, and several treatments for a chronic autoimmune disease.

Joana De Castro, the managing director of Johnson & Johnson Innovative Medicine, said the PBS listing is “long overdue.”

“For adults over 50 who live with the challenges of chronic health diseases, like COPD and asthma, RSV can be extremely serious,” said Mark Brooke, the CEO of Lung Foundation Australia.

This publication has and will continue to argue that processes like the HTA review simply cannot deliver the reform people expect because it's not an enabling policy framework. It will deliver targeted adjustments to the access barrier. Is that what stakeholders want?

The health election debate mainly concerned bulk billing. New bureaucracies are rarely the solution to anything, and the challenge of faster funded access to new health technologies, particularly when advisory committees with power appear opposed. The complexity of weight-loss therapies presents opportunities.

Roche has announced it will invest US$50 billion in the US over the next few years in a move that appears aimed at mitigating the risk of tariffs.

Pfizer has launched Part of the Story to mark World Book Day today, advocating a global campaign to help reimagine traditional cancer narratives and keep pace with science.

The release of the Trump administration's terms of reference for its trade negotiations with India has revealed no significant interest in pharmaceutical issues, despite the country's standing as one of the worst offenders on intellectual property protection.